Annual report pursuant to Section 13 and 15(d)

INCOME TAXES (Tables)

v3.24.0.1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of income before income taxes
Income before income taxes consisted of the following (in millions):
Year Ended December 31, 2023 2022 2021
United States $ 2,766  $ 3,452  $ 3,538 
International 10,186  8,234  8,887 
Total $ 12,952  $ 11,686  $ 12,425 
Schedule of income tax expense (benefit)
Income taxes consisted of the following (in millions):
United States State and Local International Total
2023        
Current $ 83  $ 129  $ 2,039  $ 2,251 
Deferred (135) (78) 211  (2)
2022        
Current $ 468  $ 118  $ 1,651  $ 2,237 
Deferred (121) (4) (122)
2021        
Current $ 243  $ 106  $ 1,378  $ 1,727 
Deferred 229  (10) 675 
1
894 
1 Includes net tax expense of $195 million related to changes in tax laws in certain foreign jurisdictions.
Reconciliation of the statutory U.S. federal tax rate and effective tax rates
A reconciliation of the statutory U.S. federal tax rate and our effective tax rate is as follows:
Year Ended December 31, 2023 2022 2021
Statutory U.S. federal tax rate 21.0  % 21.0  % 21.0  %
State and local income taxes — net of federal benefit 1.1  1.4  1.1 
Earnings in jurisdictions taxed at rates different from the statutory U.S.
   federal tax rate
(0.3) (0.6) 2.3 
2
Equity income or loss (2.1) (2.7) (2.0)
Excess tax benefits on stock-based compensation (0.3) (0.7) (0.5)
Other — net (2.0)
1
(0.3) (0.8)
3
Effective tax rate 17.4  % 18.1  % 21.1  %
1 Includes net tax benefit of $118 million (or a 0.9% impact on our effective tax rate) related to domestic provision to return adjustments, as well as for various discrete tax items. Also includes a tax benefit of $88 million (or a 0.7% impact on our effective tax rate) associated with the change in the Company’s indefinite reinvestment assertion for our Philippines and Bangladesh bottling operations.
2 Includes net tax charges of $375 million (or a 3.0% impact on our effective tax rate) related to changes in tax laws in certain foreign jurisdictions, amounts required to be recorded for changes to our uncertain tax positions, including interest and penalties, in various international jurisdictions, as well as other discrete items.
3 Includes a tax benefit of $14 million (or a 1.5% impact on our effective tax rate) associated with the $834 million gain recorded upon the acquisition of the remaining ownership interest in BodyArmor. Refer to Note 2.
Schedule of Unrecognized Tax Benefits Roll Forward
A reconciliation of the changes in the gross amount of unrecognized tax benefits is as follows (in millions):
Year Ended December 31, 2023 2022 2021
Balance of unrecognized tax benefits at beginning of year $ 926  $ 906  $ 915 
Increase related to prior period tax positions 2 
Decrease related to prior period tax positions (25) —  (50)
Increase related to current period tax positions 32  38  37 
Decrease related to settlements with taxing authorities   (2) (4)
Decrease due to lapse of the applicable statute of limitations (2) —  — 
Effect of foreign currency translation (4) (22) (1)
Balance of unrecognized tax benefits at end of year $ 929  $ 926  $ 906 
Deferred tax assets and liabilities
The tax effects of temporary differences and carryforwards that give rise to deferred tax assets and liabilities consisted of the following (in millions):
December 31, 2023 2022
Deferred tax assets:    
Property, plant and equipment $ 25  $ 40 
Trademarks and other intangible assets 1,414  1,617 
Equity method investments (including net foreign currency translation adjustments) 239  366 
Derivative financial instruments 156  207 
Other liabilities 1,709  1,503 
Benefit plans 554  522 
Net operating loss carryforwards 273  248 
Other 445  530 
Gross deferred tax assets 4,815  5,033 
Valuation allowances (396) (424)
Total deferred tax assets $ 4,419  $ 4,609 
Deferred tax liabilities:    
Property, plant and equipment $ (748) $ (741)
Trademarks and other intangible assets (1,917) (1,843)
Equity method investments (including net foreign currency translation adjustments) (1,633) (1,632)
Derivative financial instruments (282) (488)
Other liabilities (330) (372)
Benefit plans (428) (490)
Other (159) (211)
Total deferred tax liabilities $ (5,497) $ (5,777)
Net deferred tax assets (liabilities) $ (1,078) $ (1,168)
Summary of Valuation Allowance
An analysis of our deferred tax asset valuation allowances is as follows (in millions):
Year Ended December 31, 2023 2022 2021
Balance at beginning of year $ 424  $ 401  $ 406 
Additions 28  47  25 
Deductions (56) (24) (30)
Balance at end of year $ 396  $ 424  $ 401